Green factory: Plants as bioproduction platforms for recombinant proteins

Xu, Jianfeng; Dolan, Maureen C.; Medrano, Giuliana; Cramer, Carole L.; Weathers, Pamela J.

doi:10.1016/j.biotechadv.2011.08.020

Cited by 174 publications

(153 citation statements)

References 186 publications

Supporting

Mentioning

149

Contrasting

Unclassified

Order By: Relevance

“…The choice of a suitable production host and a transformation approach is the first important step in the efficient production of recombinant protein [48]. Transgenic whole plants which could be grown in the field have been used in the inexpensive and scalable production of the majority of plant-derived therapeutic proteins and will be more economical when compared to bacterial expression systems [22,49]. Different plants, including tobacco, potato, tomato, rice, corn, wheat and alfalfa have been used to express a vast variety of recombinant proteins in their leaves, seeds or tubers [23].…”

Section: Peptide Purification and Antimicrobial Activity Evaluationmentioning

confidence: 99%

See 1 more Smart Citation

Recombinant expression of LFchimera antimicrobial peptide in a plant-based expression system and its antimicrobial activity against clinical and phytopathogenic bacteria

Chahardoli

Fazeli

Niazi‎

et al. 2018

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

Antimicrobial peptides (AMPs) with their broad and selective antimicrobial activity and lowered risk of resistance development in microbial populations are promining as a new alternative candidate to conventional antibiotics. Plant-based expression systems can be employed as cost-effective and high scale-up capacity production hosts for recombinant expression of AMPs. LFchimera is a chimerical peptide containing LFcin and LFampin antimicrobial peptides of bovine lactoferrin, and it has stronger bactericidal activity. Here, the LFchimera sequence was codon-optimized for tobacco and fused with endoplasmic reticulum retention signals along with a CaMV 35S promoter and then transferred by agrobacterium-mediated transformation. The integration and expression of the transgene in tobacco plants were confirmed by polymerase chain reaction (PCR) and RT-PCR, respectively. Recombinant production of the peptide was confirmed by sodium dodecyl sulphatepolyacrylamide gel electrophoresis (SDS-PAGE), and peptide functional activity was confirmed by the antibacterial evaluation of total protein extracts against various clinical and phytopathogenic bacteria. Finally, LFchimera peptide was partially purified using an affinity column, and the antibacterial activity was shown. Taken together, these results confirmed that tobacco can be utilized for the recombinant production of antimicrobial peptides such as LFchimera.

show abstract

Section: Peptide Purification and Antimicrobial Activity Evaluationmentioning

confidence: 99%

“…Plants could successfully perform appropriate glycosylation, folding and disulphide bond formation of recombinant AMPs that are often essential for their biological activity [18]. Plant-based systems offer more advantages towards product yield, quality, homogeneity and safety compared to other systems [22][23][24][25].…”

Section: Introductionmentioning

confidence: 99%

Recombinant expression of LFchimera antimicrobial peptide in a plant-based expression system and its antimicrobial activity against clinical and phytopathogenic bacteria

Chahardoli

Fazeli

Niazi‎

et al. 2018

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

show abstract

“…Another advantage is that many plant species have a 'generally regarded as safe' status, since they do not contain mammalian viruses or pathogens, or produce endotoxins. The ease of purification and downstream processing of plant-made antibodies is often postulated to result in a low cost of the final product, which can be applied parenterally, topically or orally (Xu et al, 2012). Then there is the merit of speed: using the established state of the art tobacco leaf-based transient expression system, bulk quantities of antibodies can be manufactured in a record time as compared to any other established expression system (Castilho et al, 2011) Moreover, the developments in glyco-engineering of plants has made it possible to produce antibodies with desired glycoforms.…”

Section: Plant-based Antibody Production 589mentioning

confidence: 99%

“…Expression in transgenic plants might be a solution to effectively scale up therapeutic Igs, and lower the production costs. The recent developments in plant transformation tools have enabled effective production of almost all kinds of antibody and antibody formats, some of which, like the complex secretory IgA (SIgA) for mucosal passive immunization, have thus far been successfully manufactured only in plants , Virdi et al, 2013, Xu et al, 2012. Further, Igs with engineered human-like glycosylation can also be produced in plants (Webster and Thomas, 2012).…”

Section: Introduction and Scope Of Passive Immunizationmentioning

confidence: 99%

Role of plant expression systems in antibody production for passive immunization

Virdi¹,

Depicker²

2013

Int. J. Dev. Biol.

View full text Add to dashboard Cite

Passive immunization is a method to achieve immediate protection against infectious agents by administering pathogen-specific antibodies. It has proven to be lifesaving for many acute infections, and it is now also used for cancer treatment. Passive immunization therapies, however, are extremely expensive because they require large amounts of specific antibodies that are produced predominantly in mammalian expression systems. The cost for manufacturing plant-made antibodies is estimated to be comparatively low since plant production systems require relatively less capital investments. In addition, they are not prone to mammalian pathogens, which also eases downstream processing along with making it a safe expression system. Moreover, some of the recent developments in transient expression have enabled rapid, cGMP (current Good Manufacturing Practices) compliant manufacturing of antibodies. Whether lower production costs will be reflected in a lower market price for purified antibodies will be known when more plant-produced antibodies come to the market. Promisingly, the current molecular techniques in the field of in planta expression have enabled high-level production of a variety of antibodies in different plant organs, like roots/tubers/fruits, leaves and seeds, of a variety of plants, like potato, tobacco, maize, rice, tomato and pea, providing a very wide range of possible plant-based passive immunization therapies. For instance, the production of antibodies in edible tissues would allow for a unique, convenient, needle-less, oral passive immunization at the gastric mucosal surface. The technological advances, together with the innate capacity of plant tissues to assemble complex antibodies, will enable carving a niche in the antibody market. This non-exhaustive review aims to shed light on the role of plants as a flexible expression system for passive immunotherapy, which we envisage to progress alongside the conventional production platforms to manufacture specialized antibodies.

show abstract

“…In the past thirty years, biotechnological tools enabled scientists make important agronomic trait improvements (Cressey, 2013;Chen and Lin, 2013). In addition, plants have been developed as biofuels as well as alternative platforms for pharmaceutical protein production Xu et al, 2012). Many attempts have been also made to reengineer metabolic pathways to induce the production of health promoting compounds in natural host plants (Farré et al, 2014).…”

Section: Microscopic Analysesmentioning

confidence: 99%

Metabolic engineering of plants using a disarmed potyvirus vector

Majer¹

View full text Add to dashboard Cite

Green factory: Plants as bioproduction platforms for recombinant proteins

Cited by 174 publications

References 186 publications

Recombinant expression of LFchimera antimicrobial peptide in a plant-based expression system and its antimicrobial activity against clinical and phytopathogenic bacteria

Recombinant expression of LFchimera antimicrobial peptide in a plant-based expression system and its antimicrobial activity against clinical and phytopathogenic bacteria

Role of plant expression systems in antibody production for passive immunization

Metabolic engineering of plants using a disarmed potyvirus vector

Contact Info

Product

Resources

About